|
AU649074B2
(en)
|
1990-10-12 |
1994-05-12 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Modified ribozymes
|
|
US5652094A
(en)
|
1992-01-31 |
1997-07-29 |
University Of Montreal |
Nucleozymes
|
|
ATE291925T1
(de)
|
2001-06-05 |
2005-04-15 |
Curevac Gmbh |
Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
|
|
JP5248014B2
(ja)
|
2003-06-25 |
2013-07-31 |
ゲンシア コーポレーション |
細胞小器官トランスフェクションのための改質ベクター
|
|
AU2004297533B2
(en)
|
2003-10-24 |
2010-04-29 |
Gencia Corporation |
Methods and compositions for delivering polynucleotides
|
|
PL2578685T3
(pl)
|
2005-08-23 |
2020-01-31 |
The Trustees Of The University Of Pennsylvania |
Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
|
|
EP2049665A2
(en)
|
2006-07-28 |
2009-04-22 |
Applera Corporation |
Dinucleotide mrna cap analogs
|
|
WO2009058911A2
(en)
|
2007-10-31 |
2009-05-07 |
Applied Biosystems Inc. |
Preparation and isolation of 5' capped mrna
|
|
US9006191B2
(en)
|
2007-12-27 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Silencing of polo-like kinase expression using interfering RNA
|
|
EP3100718B1
(en)
|
2008-01-02 |
2019-11-27 |
Arbutus Biopharma Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
|
EP2279254B1
(en)
|
2008-04-15 |
2017-07-05 |
Protiva Biotherapeutics Inc. |
Novel lipid formulations for nucleic acid delivery
|
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
|
AU2009303345B2
(en)
|
2008-10-09 |
2015-08-20 |
Arbutus Biopharma Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
WO2010048536A2
(en)
|
2008-10-23 |
2010-04-29 |
Alnylam Pharmaceuticals, Inc. |
Processes for preparing lipids
|
|
EP3699172A3
(en)
|
2008-11-10 |
2020-11-18 |
Arbutus Biopharma Corporation |
Novel lipids and compositions for the delivery of therapeutics
|
|
EP2391343B1
(en)
|
2009-01-29 |
2017-03-01 |
Arbutus Biopharma Corporation |
Improved lipid formulation for the delivery of nucleic acids
|
|
CA3042927C
(en)
|
2009-05-05 |
2022-05-17 |
Arbutus Biopharma Corporation |
Lipid compositions for the delivery of therapeutic agents
|
|
KR20220038506A
(ko)
|
2009-06-10 |
2022-03-28 |
알닐람 파마슈티칼스 인코포레이티드 |
향상된 지질 조성물
|
|
KR101161622B1
(ko)
*
|
2009-08-31 |
2012-07-04 |
헬릭스 주식회사 |
번역 효율 증진용 ｄｎａ 단편 및 이를 포함하는 재조합 벡터
|
|
SI2506857T1
(en)
|
2009-12-01 |
2018-08-31 |
Translate Bio, Inc. |
Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases
|
|
EP4481047A3
(en)
|
2010-06-03 |
2025-04-16 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
US9006417B2
(en)
|
2010-06-30 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
|
KR20220025112A
(ko)
|
2011-06-08 |
2022-03-03 |
샤이어 휴먼 지네틱 테라피즈 인크. |
Mrna 전달을 위한 지질 나노입자 조성물 및 방법
|
|
PT3682905T
(pt)
|
2011-10-03 |
2022-04-07 |
Modernatx Inc |
Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
|
|
DK3421601T3
(da)
|
2011-12-30 |
2020-02-24 |
Cellscript Llc |
Fremstilling og anvendelse af in-vitro-syntetiseret ssRNA til indføring i pattedyrceller med henblik på at inducere en biologisk eller biokemisk effekt
|
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
|
US20140090108A1
(en)
|
2012-09-18 |
2014-03-27 |
Freydoun Garabagi |
Vectors and Methods For Enhancing Recombinant Protein Expression in Plants
|
|
WO2014093924A1
(en)
|
2012-12-13 |
2014-06-19 |
Moderna Therapeutics, Inc. |
Modified nucleic acid molecules and uses thereof
|
|
WO2014130722A1
(en)
|
2013-02-20 |
2014-08-28 |
Valerion Therapeutics, Llc |
Methods and compositions for treatment of forbes-cori disease
|
|
WO2014164253A1
(en)
|
2013-03-09 |
2014-10-09 |
Moderna Therapeutics, Inc. |
Heterologous untranslated regions for mrna
|
|
US8912147B2
(en)
|
2013-04-15 |
2014-12-16 |
BioBlast Pharma Ltd. |
Mitochondrial proteins constructs and uses thereof
|
|
AU2014296278C1
(en)
|
2013-07-30 |
2023-02-02 |
Genevant Sciences Gmbh |
Block copolymers and their conjugates or complexes with oligonucleotides
|
|
EP3052511A4
(en)
|
2013-10-02 |
2017-05-31 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
|
EP3574923A1
(en)
|
2013-10-22 |
2019-12-04 |
Translate Bio, Inc. |
Mrna therapy for phenylketonuria
|
|
CN110003066B
(zh)
|
2013-11-18 |
2021-09-03 |
阿克丘勒斯治疗公司 |
用于rna递送的可电离的阳离子脂质
|
|
BR112016020688B1
(pt)
|
2014-03-09 |
2024-01-30 |
The Trustees Of The University Of Pennsylvania |
Vetores virais recombinantes, vírus adenoassociado recombinante, composição farmacêutica, bem como uso dos mesmos
|
|
EP3154570A4
(en)
|
2014-06-13 |
2017-12-27 |
Valerion Therapeutics, LLC |
Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders
|
|
WO2016070166A2
(en)
|
2014-11-02 |
2016-05-06 |
Arcturus Therapeutics, Inc. |
Messenger una molecules and uses thereof
|
|
EP3461904A1
(en)
|
2014-11-10 |
2019-04-03 |
ModernaTX, Inc. |
Alternative nucleic acid molecules containing reduced uracil content and uses thereof
|
|
EP4324473A3
(en)
|
2014-11-10 |
2024-05-29 |
ModernaTX, Inc. |
Multiparametric nucleic acid optimization
|
|
DK3221293T3
(da)
|
2014-11-18 |
2023-04-03 |
Arcturus Therapeutics Inc |
Ioniserbar kationisk lipid til RNA-afgivelse
|
|
US9709490B2
(en)
|
2014-12-08 |
2017-07-18 |
Canon Kabushiki Kaisha |
Refractive index distribution measuring method, refractive index distribution measuring apparatus, and optical element manufacturing method
|
|
EP3247328B1
(en)
|
2015-01-21 |
2026-01-07 |
Genevant Sciences Gmbh |
Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
|
|
EP3328439B1
(en)
|
2015-07-31 |
2020-04-08 |
Arcturus Therapeutics, Inc. |
Multiligand agent for drug delivery
|
|
DK4276189T3
(da)
|
2015-09-21 |
2026-05-26 |
Trilink Biotechnologies Llc |
Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe
|
|
WO2017100551A1
(en)
|
2015-12-09 |
2017-06-15 |
Alexion Pharmaceuticals, Inc. |
HETEROLOGOUS UTR SEQUENCES FOR ENHANCED mRNA EXPRESSION
|
|
US9834510B2
(en)
|
2015-12-30 |
2017-12-05 |
Arcturus Therapeutics, Inc. |
Aromatic ionizable cationic lipid
|
|
AU2017283479B2
(en)
|
2016-06-13 |
2023-08-17 |
Translate Bio, Inc. |
Messenger RNA therapy for the treatment of ornithine transcarbamylase deficiency
|
|
IL264439B2
(en)
|
2016-08-17 |
2024-08-01 |
Factor Bioscience Inc |
non-viral, cell-free composition comprising a synthetic messenger RNA (MRNA) encoding a gene-editing protein for use in treating cancer, and a synthetic RNA encoding a gene-editing protein for use in treatment
|
|
US10487105B2
(en)
|
2016-10-19 |
2019-11-26 |
Arcturus Therapeutics, Inc. |
Trinucleotide MRNA cap analogs
|
|
KR20190093816A
(ko)
|
2016-10-26 |
2019-08-26 |
큐어백 아게 |
지질 나노입자 mRNA 백신
|
|
JP7560946B2
(ja)
|
2016-11-10 |
2024-10-03 |
トランスレイト バイオ， インコーポレイテッド |
メッセンジャーｒｎａの皮下送達
|
|
US10383952B2
(en)
|
2016-12-21 |
2019-08-20 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipid for RNA delivery
|
|
US10526284B2
(en)
|
2016-12-21 |
2020-01-07 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipid for RNA delivery
|
|
WO2018119163A1
(en)
|
2016-12-21 |
2018-06-28 |
Payne Joseph E |
Ionizable cationic lipid for rna delivery
|
|
US11104887B2
(en)
|
2017-01-03 |
2021-08-31 |
Ethris Gmbh |
Ornithine transcarbamylase coding polyribonucleotides and formulations thereof
|
|
US10227302B2
(en)
|
2017-02-09 |
2019-03-12 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipid for RNA delivery
|
|
EP3589290A4
(en)
|
2017-02-28 |
2020-12-30 |
Arcturus Therapeutics, Inc. |
Translatable molecules and synthesis thereof
|
|
US11015204B2
(en)
|
2017-05-31 |
2021-05-25 |
Arcturus Therapeutics, Inc. |
Synthesis and structure of high potency RNA therapeutics
|
|
KR102636537B1
(ko)
|
2017-05-31 |
2024-02-15 |
울트라제닉스 파마수티컬 인코포레이티드 |
글리코겐 축적 질환 유형 iii에 대한 치료제
|
|
EP3714048B1
(en)
*
|
2017-11-22 |
2025-04-09 |
ModernaTX, Inc. |
Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
|
|
MA51306A
(fr)
|
2017-12-20 |
2020-10-28 |
Translate Bio Inc |
Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
|
|
CA3122080A1
(en)
|
2018-12-06 |
2020-06-11 |
Arcturus Therapeutics, Inc. |
Compositions and methods for treating ornithine transcarbamylase deficiency
|
|
EP3942050A4
(en)
|
2019-03-19 |
2023-02-22 |
Arcturus Therapeutics, Inc. |
PROCEDURE FOR THE PRODUCTION OF LIPID-COATED RNA NANOPARTICLES
|
|
EP4114470A4
(en)
|
2020-03-03 |
2024-04-17 |
Arcturus Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY
|